Maria Chaparro

Summary

Publications

  1. doi request reprint Treatment of inflammatory bowel disease: what's new in Digestive Disease Week 2016
    Maria Chaparro
    Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa IIS IP y Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Madrid, España Electronic address
    Gastroenterol Hepatol 39:20-28. 2016
  2. doi request reprint [New molecules in the treatment of inflammatory bowel disease]
    Maria Chaparro
    Servicio de Aparato Digestivo, Hospital Universitario de La Princesa e Instituto de Investigación Sanitaria Princesa IIS IP, Madrid, España Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, España Electronic address
    Gastroenterol Hepatol 39:411-23. 2016
  3. doi request reprint Outcome after a dose "de-intensification" strategy with anti-TNF drugs in patients with Crohn's disease
    Maria Chaparro
    Gastroenterology Department, La Princesa, Instituto de Investigación Sanitaria Princesa IP, Madrid, Spain Electronic address
    Gastroenterol Hepatol 39:255-60. 2016
  4. doi request reprint [Natural history, complications, safety and pregnancy in inflammatory bowel disease]
    Maria Chaparro
    Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa IIS IP y Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Madrid, España Electronic address
    Gastroenterol Hepatol 38:20-31. 2015
  5. doi request reprint How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease?
    Maria Chaparro
    Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa IP, and Centro de Investigación Biomédica en Red de enfermedades hepáticas y digestivas CIBERehd, Americio 17, E 2 C, 28021 Madrid, Spain 34 913093911 34 914022299
    Expert Opin Drug Saf 13:1749-62. 2014
  6. doi request reprint [Role of thiopurine agents in ulcerative colitis]
    Maria Chaparro
    Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa IP, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, Madrid, España Electronic address
    Gastroenterol Hepatol 34:30-5. 2011
  7. doi request reprint [What useful developments for my inflammatory bowel disease practice have come from Digestive Disease Week 2014?]
    Maria Chaparro
    Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Madrid, España Instituto de Investigación Sanitaria Princesa IP y Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD Electronic address
    Gastroenterol Hepatol 37:22-30. 2014
  8. doi request reprint [Role of thiopurine agents in ulcerative colitis]
    Maria Chaparro
    Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa IP, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, Madrid, Espana
    Gastroenterol Hepatol 34:30-5. 2011
  9. doi request reprint Health care costs of complex perianal fistula in Crohn's disease
    M Chaparro
    Servicio de Aparato Digestivo del Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa IP, Playa de Mojácar 29 Urb Bonanza, 28669, Boadilla del Monte, Madrid, Spain
    Dig Dis Sci 58:3400-6. 2013
  10. doi request reprint [New advances in the treatment of inflammatory bowel disease]
    Maria Chaparro
    Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa IP y Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Madrid, España Electronic address
    Gastroenterol Hepatol 36:21-9. 2013

Collaborators

Detail Information

Publications60

  1. doi request reprint Treatment of inflammatory bowel disease: what's new in Digestive Disease Week 2016
    Maria Chaparro
    Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa IIS IP y Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Madrid, España Electronic address
    Gastroenterol Hepatol 39:20-28. 2016
    ....
  2. doi request reprint [New molecules in the treatment of inflammatory bowel disease]
    Maria Chaparro
    Servicio de Aparato Digestivo, Hospital Universitario de La Princesa e Instituto de Investigación Sanitaria Princesa IIS IP, Madrid, España Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, España Electronic address
    Gastroenterol Hepatol 39:411-23. 2016
    ..Finally, in the next few years, studies should aim to identify factors predictive of response to the distinct biological agents for IBD in order to allow personalized selection of the best therapeutic alternative for each patient. ..
  3. doi request reprint Outcome after a dose "de-intensification" strategy with anti-TNF drugs in patients with Crohn's disease
    Maria Chaparro
    Gastroenterology Department, La Princesa, Instituto de Investigación Sanitaria Princesa IP, Madrid, Spain Electronic address
    Gastroenterol Hepatol 39:255-60. 2016
    ..Once patients have achieved remission, dose "de-intensification" can be used for cost and safety reasons...
  4. doi request reprint [Natural history, complications, safety and pregnancy in inflammatory bowel disease]
    Maria Chaparro
    Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa IIS IP y Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Madrid, España Electronic address
    Gastroenterol Hepatol 38:20-31. 2015
    ....
  5. doi request reprint How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease?
    Maria Chaparro
    Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa IP, and Centro de Investigación Biomédica en Red de enfermedades hepáticas y digestivas CIBERehd, Americio 17, E 2 C, 28021 Madrid, Spain 34 913093911 34 914022299
    Expert Opin Drug Saf 13:1749-62. 2014
    ..Infliximab has been approved for the treatment of patients with inflammatory bowel diseases (IBD). However, data regarding its safety during pregnancy and breastfeeding are scarce...
  6. doi request reprint [Role of thiopurine agents in ulcerative colitis]
    Maria Chaparro
    Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa IP, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, Madrid, España Electronic address
    Gastroenterol Hepatol 34:30-5. 2011
    ....
  7. doi request reprint [What useful developments for my inflammatory bowel disease practice have come from Digestive Disease Week 2014?]
    Maria Chaparro
    Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Madrid, España Instituto de Investigación Sanitaria Princesa IP y Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD Electronic address
    Gastroenterol Hepatol 37:22-30. 2014
    ..The causal link between psychological factors and the occurrence of IBD relapse is by no means established. ..
  8. doi request reprint [Role of thiopurine agents in ulcerative colitis]
    Maria Chaparro
    Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa IP, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, Madrid, Espana
    Gastroenterol Hepatol 34:30-5. 2011
    ....
  9. doi request reprint Health care costs of complex perianal fistula in Crohn's disease
    M Chaparro
    Servicio de Aparato Digestivo del Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa IP, Playa de Mojácar 29 Urb Bonanza, 28669, Boadilla del Monte, Madrid, Spain
    Dig Dis Sci 58:3400-6. 2013
    ..To evaluate the use of health care resources and the associated costs of complex perianal Crohn's disease (CD) from the National Health System perspective...
  10. doi request reprint [New advances in the treatment of inflammatory bowel disease]
    Maria Chaparro
    Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa IP y Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Madrid, España Electronic address
    Gastroenterol Hepatol 36:21-9. 2013
    ..The preliminary results of the ASTIC trial were reported, which evaluated the safety and efficacy of bone marrow transplantation in Crohn's disease. ..
  11. doi request reprint Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients
    Maria Chaparro
    Gastroenterology Unit, La Princesa and Instituto de Investigación Sanitaria Princesa IP, Madrid, Spain
    Inflamm Bowel Dis 19:1404-10. 2013
    ..To evaluate the safety of thiopurines in patients with inflammatory bowel disease. To identify predictive factors associated with the development of thiopurine-induced adverse events...
  12. doi request reprint Dysplasia and colorectal cancer in a patient with ulcerative colitis and primary sclerosing cholangitis: a case report and a short review of the literature
    Maria Chaparro
    Department of Gastroenterology, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain
    J Crohns Colitis 7:e61-5. 2013
    ..Surveillance for colorectal cancer should be strongly recommended in this group of patients...
  13. pmc Effectiveness of infliximab after adalimumab failure in Crohn's disease
    Maria Chaparro
    Department of Gastroenterology, Hospital Universitario de la Princesa, Instituto de Investigación Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, 28006 Madrid, Spain
    World J Gastroenterol 18:5219-24. 2012
    ..To evaluate the effectiveness of infliximab as a second-line therapy in Crohn's disease patients after adalimumab failure...
  14. doi request reprint [Advances in the efficacy, optimization and safety of treatments for inflammatory bowel disease]
    Maria Chaparro
    Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa IP y Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Madrid, Spain
    Gastroenterol Hepatol 35:57-67. 2012
    ....
  15. doi request reprint [Advances in the management of ulcerative colitis presented at Digestive Disease Week 2011]
    Maria Chaparro
    Servicio de Aparato Digestivo, Hospital Universitario de Princesa, Instituto de Investigación Sanitaria Princesa, Madrid, Espana
    Gastroenterol Hepatol 34:52-9. 2011
    ....
  16. doi request reprint Long-term durability of response to adalimumab in Crohn's disease
    M Chaparro
    Gastroenterology Units of Hospital de La Princesa and Instituto de Investigación Sanitaria Princesa, IP, Madrid, Spain
    Inflamm Bowel Dis 18:685-90. 2012
    ..Few reports provide insight into the durability of treatment of CD with adalimumab for periods longer than 12 months in clinical practice...
  17. doi request reprint Intensification of infliximab therapy in Crohn's disease: efficacy and safety
    - M Chaparro
    Gastroenterology Units of Hospital de Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain
    J Crohns Colitis 6:62-7. 2012
    ..The response of Crohn's disease (CD) to infliximab is initially good, although a loss of efficacy is observed over time. Dose escalation has been recommended in such cases...
  18. ncbi request reprint [Esophagic multichannel intraluminal impedance. Technical bases and clinical applications]
    Maria Chaparro
    Hospital Universitario de la Princesa, Madrid, Espana
    Med Clin (Barc) 129:510-2. 2007
  19. doi request reprint Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study
    M Chaparro
    Gastroenterology Department, Hospital Universitario de La Princesa and Instituto de Investigación Sanitaria Princesa, Madrid, Spain
    Aliment Pharmacol Ther 35:275-83. 2012
    ..When therapy with this drug fails, infliximab can be considered to avoid colectomy. The efficacy and safety of this sequential approach remain unknown...
  20. ncbi request reprint Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease
    Maria Chaparro
    Gastroenterology Unit, Hospital Universitario de la Princesa, Diego de Leon 62, 28006, Madrid, Spain
    Curr Pharm Biotechnol 12:765-73. 2011
    ..Infliximab and adalimumab bind the FcRn-receptor as other IgG proteins do. The mechanisms of the diffusion of certolizumab across the placenta barrier remain unknown...
  21. doi request reprint Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response
    Maria Chaparro
    Gastroenterology Unit of Hospital La Princesa, Madrid, Spain
    J Clin Gastroenterol 45:113-8. 2011
    ..The efficacy of infliximab therapy in patients with Crohn's disease (CD) is unknown beyond 12 months. For patients who lose their initial response, consideration can be given to dose "escalation" to regain therapeutic benefit...
  22. doi request reprint Prospective evaluation of a clinical guideline recommending early patients discharge in bleeding peptic ulcer
    Maria Chaparro
    Gastroenterology Unit, La Princesa University Hospital and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain
    J Gastroenterol Hepatol 25:1525-9. 2010
    ..To validate an early discharge policy in patients admitted with upper gastrointestinal bleeding (UGIB) due to ulcers...
  23. ncbi request reprint Computed tomography colonography compared with conventional colonoscopy for the detection of colorectal polyps
    María Chaparro Sánchez
    Department of Gastroenterology and Hepatology, University Hospital La Princesa, Madrid, Spain
    Gastroenterol Hepatol 30:375-80. 2007
    ..To determine the diagnostic accuracy of computed tomography colonography (CTC) compared with conventional colonoscopy (CC)...
  24. doi request reprint Accuracy of computed tomographic colonography for the detection of polyps and colorectal tumors: a systematic review and meta-analysis
    Maria Chaparro
    Department of Gastroenterology and Hepatology, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain
    Digestion 80:1-17. 2009
    ..The real accuracy of computed tomographic colonography (CTC) is still unknown...
  25. ncbi request reprint [Potential impact of contrast-enhanced ultrasonography in the study of focal liver lesions]
    Maria Chaparro
    Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Madrid, Espana
    Med Clin (Barc) 131:73-7. 2008
    ....
  26. ncbi request reprint Mechanisms of angiogenesis in chronic inflammatory liver disease
    Maria Chaparro
    Hepatology Department and Ciberehd University Hospital La Princesa Universidad Autonoma de Madrid Spain
    Ann Hepatol 6:208-13. 2007
    ..This review examines the potential pathogenic role of angiogenesis in the context of viral hepatitis, autoinmmune hepatitis, primary biliary cirrhosis and hepatocellular carcinoma...
  27. doi request reprint Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study
    Ivan Guerra
    1Department of Gastroenterology, Hospital Universitario de Fuenlabrada, Madrid, Spain 2Department of Gastroenterology, Hospital Clinic, Barcelona, Spain 3Department of Gastroenterology, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD 4Department of Gastroenterology, Hospital Universitario La Fe, Valencia, Spain 5Department of Gastroenterology, Consorci Sanitari de Terrassa, Barcelona, Spain 6Department of Gastroenterology, Corporacio Sanitaria Parc Tauli, Sabadell, Spain 7Department of Gastroenterology, Hospital Universitario La Princesa, Instituto de Investigación Sanitaria Princesa IIS IP, Madrid, Spain 8Department of Gastroenterology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain 9Department of Gastroenterology, Hospital de Manises, Valencia, Spain 10Department of Gastroenterology, Hospital Clinico de Valencia, Universitat de Valencia, Valencia, Spain 11Department of Gastroenterology, Hospital de Basurto, Bilbao, Spain 12Department of Gastroenterology, Hospital del Mar, Barcelona, Spain 13Department of Gastroenterology, Hospital Universitario de Salamanca, Salamanca, Spain 14Department of Gastroenterology
    Inflamm Bowel Dis 22:894-901. 2016
    ..Psoriasis induced by anti-tumor necrosis factor-α (TNF) therapy has been described as a paradoxical side effect...
  28. doi request reprint Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis
    Carlos Taxonera
    Inflammatory Bowel Disease Unit, Department of Gastroenterology, Hospital Clinico San Carlos, C Profesor Martin Lagos s n, 28040, Madrid, Spain
    Dig Dis Sci 60:3075-84. 2015
    ..The outcomes of infliximab dose escalation in ulcerative colitis (UC) have not been well evaluated...
  29. doi request reprint How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study
    Fernando Bermejo
    Department of Gastroenterology, Hospital Universitario de Fuenlabrada, Madrid, Spain Electronic address
    Dig Liver Dis 45:733-7. 2013
    ..Tuberculosis reactivation can lead to severe complications in patients treated with anti-tumour necrosis factor-alpha...
  30. ncbi request reprint Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation
    Carlos Taxonera
    Inflammatory Bowel Disease Unit, Department of Gastroenterology, Hospital Clinico San Carlos, C Profesor Martin Lagos s n, 28040, Madrid, Spain
    Dig Dis Sci . 2016
    ..The impact of prior anti-TNF use on "real-life" outcomes of adalimumab therapy in ulcerative colitis (UC) is not well known...
  31. doi request reprint Relationship between levels of angiogenic and lymphangiogenic factors and the endoscopic, histological and clinical activity, and acute-phase reactants in patients with inflammatory bowel disease
    Alicia Algaba
    Department of Gastroenterology of the Hospital Universitario de Fuenlabrada, Madrid, Spain Electronic address
    J Crohns Colitis 7:e569-79. 2013
    ....
  32. doi request reprint The effects of infliximab or adalimumab on vascular endothelial growth factor and angiopoietin 1 angiogenic factor levels in inflammatory bowel disease: serial observations in 37 patients
    Alicia Algaba
    Department of Gastroenterology, Hospital Universitario de Fuenlabrada, Madrid, Spain Gastroenterology Unit, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa, Madrid, Spain Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain Gastroenterology Unit, Hospital de Sabadell, Institut Parc Taulí, Sabadell, Barcelona, Spain and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain
    Inflamm Bowel Dis 20:695-702. 2014
    ..The aim of the study was to compare the concentrations of angiogenic proteins in patients with inflammatory bowel disease (IBD) and healthy controls and to analyze changes in the levels during infliximab and adalimumab treatment...
  33. doi request reprint Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease
    Cristina López-Martín
    Gastroenterology Unit, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain
    Gastroenterol Hepatol 34:385-92. 2011
    ..Thiopurine immunomodulators are the most commonly used immunosuppressants in inflammatory bowel disease...
  34. doi request reprint Outcomes of Medical and Surgical Therapy for Entero-urinary Fistulas in Crohn's Disease
    Carlos Taxonera
    Inflammatory Bowel Disease Unit, Department of Gastroenterology, Hospital Clinico San Carlos and Instituto de Investigacion del Hospital Clinico San Carlos IdISSC, Madrid, Spain
    J Crohns Colitis 10:657-62. 2016
    ..The aims of this study were to evaluate the frequency of entero-urinary fistulas in a cohort of Crohn's disease (CD) patients and to analyse the outcomes of medical and surgical therapy...
  35. doi request reprint Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience
    José Ignacio Fortea-Ormaechea
    Digestive Disease Department, Hospital Gregorio Maranon, Madrid, Spain
    Gastroenterol Hepatol 34:443-8. 2011
    ..To evaluate effectiveness and safety of adalimumab in CD patients of the Madrid area and identify predictors of response...
  36. doi request reprint Effectiveness of anti-TNFα drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNFα agent
    María Del Carmen R-Grau
    Department of Gastroenterology, La Princesa, Instituto de Investigación Sanitaria Princesa IIS IP, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, Madrid, Spain Electronic address
    Dig Liver Dis 48:613-9. 2016
    ..Anti-TNF treatment is effective for Crohn's disease (CD); however, some patients did not achieve remission with these drugs...
  37. doi request reprint Should we monitor vitamin B12 and folate levels in Crohn's disease patients?
    Fernando Bermejo
    Department of Gastroenterology, Hospital Universitario de Fuenlabrada, Madrid, Spain
    Scand J Gastroenterol 48:1272-7. 2013
    ..Our aim was to define the prevalence of vitamin B12 and folate deficiency in patients with Crohn's disease and to identify predictive factors associated with such abnormalities...
  38. doi request reprint H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy
    Jean François Rahier
    Gastroenterology Unit, Cliniques Universitaires UCL Mont Godinne, Yvoir, Belgium
    Gut 60:456-62. 2011
    ..Safety data are lacking on influenza vaccination in general and on A (H1N1)v vaccination in particular in patients with inflammatory bowel disease (IBD) receiving immmunomodulators and/or biological therapy...
  39. pmc High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life
    Santiago García-López
    Department of Gastroenterology, University Hospital Miguel Servet, Zaragoza, Spain
    Blood Transfus 14:199-205. 2016
    ..Clinical trials have shown intravenous iron to be effective and well tolerated. However, published experience in clinical practice with specific evaluation of the effect on quality of life is limited...
  40. doi request reprint Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort
    Sam Khorrami
    Servicio de Aparato Digestivo, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria de Palma IdISPa, Palma de Mallorca, Spain Servicio de Aparato Digestivo, Hospital Universitario Gregorio Maranon, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa IIS IP, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, Madrid, Spain Servicio de Aparato Digestivo, Complejo Hospitalario de Leon, Leon, Spain Servicio de Aparato Digestivo, Hospital Universitario y Politécnico La Fe, CIBERehd, Valencia, Spain Servicio de Aparato Digestivo, Complejo Asistencial Universitario de Burgos, Burgos, Spain Servicio de Aparato Digestivo, Hospital Universitario Reina Sofia, IMIBIC, Cordoba, Spain Servicio de Aparato Digestivo, Hospital Universitario Puerta de Hierro, Madrid, Spain Servicio de Aparato Digestivo, Corporació Sanitària Universitària Parc Taulí, CIBERehd, Instituto de Salud Carlos III, Sabadell, Spain Servicio de Aparato Digestivo, Hospital Clinico San Carlos, Instituto de Investigación del Hospital Clínico San Carlos IdISSC, Madrid, Spain Servicio de Aparato Digestivo
    Inflamm Bowel Dis 22:1662-9. 2016
    ..This study aims to assess the effectiveness and safety of ustekinumab in refractory patients with CD in real-life practice...
  41. ncbi request reprint Measurement of anti-TNF agents and anti-drug antibodies serum levels in patients with inflammatory bowel disease
    Ivan Guerra
    Gastroenterology Department Hospital Universitario de Fuenlabrada Camino del Molino, 2 28942, Fuenlabrada, Madrid, Spain
    Curr Drug Metab 15:875-81. 2014
    ....
  42. doi request reprint Vaccination strategies in patients with IBD
    Javier P Gisbert
    Gastroenterology Unit, Hospital Universitario de la Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Diego de Leon 62, Madrid 28006, Spain
    Nat Rev Gastroenterol Hepatol 10:277-85. 2013
    ..Therefore, vaccination status should be checked and updated upon diagnosis of IBD...
  43. doi request reprint Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease
    Javier P Gisbert
    Gastroenterology Unit, Hospital Universitario de la Princesa and Instituto de Investigación Sanitaria Princesa IP, Madrid, Spain
    Am J Gastroenterol 108:1426-38. 2013
    ..However, data regarding their safety during pregnancy and breastfeeding are scarce. The aim of this study was to critically review available data on the safety of anti-TNF therapy during pregnancy and breastfeeding in women with IBD...
  44. doi request reprint Kinetics of anti-hepatitis B surface antigen titers after hepatitis B vaccination in patients with inflammatory bowel disease
    Javier P Gisbert
    Department of Gastroenterology, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa, Madrid, Spain
    Inflamm Bowel Dis 19:554-8. 2013
    ....
  45. pmc Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin
    Maria Trapero-Marugan
    Gastroenterology Hepatology Department, University Hospital La Princesa and Princesa Research Institute, Autonomous University of Madrid and CIBERehd, C Diego de Leon 62, Madrid, Spain
    World J Gastroenterol 17:493-8. 2011
    ..To assess the clinical, biochemical and virological long-term outcome in chronic hepatitis C (CHC) patients with a sustained virological response (SVR) after peginterferon (PEG-IFN) plus ribavirin combination therapy...
  46. doi request reprint Clinical Course of Bone Metabolism Disorders in Patients with Inflammatory Bowel Disease: A 5-Year Prospective Study
    Fernando Casals-Seoane
    Gastroenterology Unit, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa IIS IP and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Madrid, Spain
    Inflamm Bowel Dis 22:1929-36. 2016
    ..The objective was to study the course of BMD disorders in patients with IBD, analyze the factors influencing their development, and assess the effect of treatment with calcium, vitamin D, and bisphosphonates...
  47. doi request reprint The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
    Javier P Gisbert
    Gastroenterology Unit, Hospital Universitario de La Princesa and Instituto de Investigación Sanitaria Princesa IIS IP, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, Madrid, Spain
    Am J Gastroenterol 111:632-47. 2016
    ....
  48. doi request reprint Effectiveness of adalimumab in perianal fistulas in crohn's disease patients naive to anti-TNF therapy
    Carlos Castaño-Milla
    Services of Gastroenterology, Hospital Universitario de la Princesa, Madrid Hospital de Cabueñes, Gijon, Asturias Hospital Clínico Universitario de Santiago, Santiago de Compostela, Galicia Hospital Universitario Reina Sofía, Murcia Hospital de Donostia, Instituto Biodonostia, Universidad del Pais Vasco, Leioa Hospital de Galdakao Usánsolo, Galdakao, Bizkaia Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, San Sebastián Complejo Hospitalario de Pontevedra, Pontevedra Hospital de León, León Hospital de la Santa Creu i Sant Pau Departament de Medicina, Corporació Sanitària Universitària Parc Taulí, Universitat Autonoma de Barcelona, Sardañola del Vallés Consorci Sanitari de Terrassa, Terrassa Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Sabadell, Barcelona, Spain
    J Clin Gastroenterol 49:34-40. 2015
    ..Data regarding the effectiveness of adalimumab (ADA) in the treatment of perianal fistula in patients with Crohn's disease (CD) naive to antitumor necrosis factor (TNF) therapy are scarce...
  49. doi request reprint Angiopoietins in inflammation and their implication in the development of inflammatory bowel disease. A review
    Pablo M Linares
    Gastroenterology Unit, Hospital Universitario de la Princesa and Instituto de Investigación Sanitaria Princesa IP, Madrid, Spain Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Spain Electronic address
    J Crohns Colitis 8:183-90. 2014
    ....
  50. doi request reprint Probable diffuse retinopathy caused by adalimumab in a patient with Crohn's disease
    Paula Marticorena-Álvarez
    Department of Ophthalmology, Hospital Universitario de La Princesa e Instituto de Investigación Sanitaria Princesa IP, Madrid, Spain
    J Crohns Colitis 6:950-3. 2012
    ..To our knowledge, this is the first report of diffuse retinopathy probable caused by systemic administration of adalimumab. This form of retinal toxicity should be considered in patients with disorders of vision treated with this drug...
  51. doi request reprint Clinical patterns and outcomes of ischaemic colitis: results of the Working Group for the Study of Ischaemic Colitis in Spain (CIE study)
    Miguel A Montoro
    Department of Gastroenterology, Hospital San Jorge, Huesca, Spain
    Scand J Gastroenterol 46:236-46. 2011
    ..We performed such a study to evaluate the clinical presentation, outcome, and mortality as well as clinical variables associated with poor prognosis...
  52. pmc Angiogenesis: from chronic liver inflammation to hepatocellular carcinoma
    Paloma Sanz-Cameno
    Laboratory of Investigation, Molecular Biology Unit, Hospital Universitario de la Princesa, Universidad Autonoma de Madrid, 28006 Madrid, Spain
    J Oncol 2010:272170. 2010
    ....
  53. pmc Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease
    Javier P Gisbert
    Javier P Gisbert, María Chaparro, Gastroenterology Unit, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa IP and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, 28006 Madrid, Spain
    World J Gastroenterol 17:3467-78. 2011
    ..Finally, thiopurine methyltransferase (TPMT) screening cannot substitute for regular monitoring because the majority of cases of myelotoxicity are not TPMT-related...
  54. doi request reprint Correlation between serological biomarkers and endoscopic activity in patients with inflammatory bowel disease
    Pablo Miranda-García
    Gastroenterology Department, Hospital Universitario Quirón, Madrid, Spain Electronic address
    Gastroenterol Hepatol 39:508-15. 2016
    ..Biological markers have been routinely used as a non-invasive means of determining disease activity. The aim of this study was to determine the correlation between common biological markers and endoscopic activity in IBD...
  55. doi request reprint Maintenance therapy options for ulcerative colitis
    Maria Chaparro
    a Gastroenterology Unit, Hospital Universitario de La Princesa and Instituto de Investigación Sanitaria Princesa IIS IP, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, Madrid, Spain
    Expert Opin Pharmacother 17:1339-49. 2016
    ..Medical therapy is the cornerstone of the management of ulcerative colitis (UC) and the goal of the treatment is the induction and maintenance of remission...
  56. pmc Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease
    Alicia C Marin
    Alicia C Marín, Javier P Gisbert, María Chaparro, Gastroenterology Unit, Hospital Universitario de La Princesa and Instituto de Investigación Sanitaria Princesa, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, 28021 Madrid, Spain
    World J Gastroenterol 21:11273-81. 2015
    ..A better understanding of the immune response, specifically to vaccines, in patients with immune-mediated diseases (such as IBD), is crucial when developing vaccines that trigger more potent immunologic responses. ..
  57. doi request reprint Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?
    Javier P Gisbert
    Gastroenterology Unit, Hospital Universitario de la Princesa and Instituto de Investigación Sanitaria Princesa IP, Madrid, Spain
    Scand J Gastroenterol 50:379-86. 2015
    ..Some patients with inflammatory bowel disease (IBD) never respond or lose their response to a second anti-TNF...
  58. pmc Adalimumab-induced interstitial pneumonia in a patient with Crohn's disease
    María José Casanova
    María José Casanova, María Chaparro, Javier P Gisbert, Gastroenterology Department, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa IIS IP, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, CP 28002 Madrid, Spain
    World J Gastroenterol 21:2260-2. 2015
    ..A compatible pattern in the biopsy and the clinical improvement after discontinuation of the anti-TNF drug would strongly support the diagnosis. ..
  59. doi request reprint [Evaluation of the concordance between biological markers and clinical activity in inflammatory bowel disease]
    Pablo Miranda García
    Servicio de Aparato Digestivo, Hospital Universitario Quirón, Madrid, España Electronic address
    Med Clin (Barc) 144:9-13. 2015
    ....
  60. doi request reprint Validation of a genotyping method for analysis of TPMT polymorphisms
    Manuel Román
    Clinical Pharmacology Service, Hospital Universitario de la Princesa, Instituto Teofilo Hernando, UAM, Instituto de Investigación Sanitaria Princesa IP, Madrid, Spain
    Clin Ther 34:878-84. 2012
    ..Several mutations in the TPMT gene correlate with low enzyme activity and adverse effects such as myelotoxicity. Hence, genotyping TPMT makes it possible to identify patients at high risk for drug toxicity...